Navigation Links
Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 8, 2007
Date:10/30/2007

Conference Call and Webcast to Follow

ROCKVILLE, Md., Oct. 30 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced it will release results for the quarter ended September 30, 2007, on Thursday, November 8, 2007, before the market opens. A full text copy of the release will be disseminated at that time.

Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will host a conference call to discuss the results and other corporate developments at 10:30 AM ET on Thursday, November 8, 2007. Also participating on the call will be Steven A. Shallcross, Senior Vice President and CFO. To participate in the conference call, dial the appropriate number below shortly before the 10:30 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos.

The teleconference dial-in numbers are as follows:

Domestic callers 1-866-578-5801

International callers 1-617-213-8058

The conference call will be broadcast simultaneously and archived on the Company's Web site, http://www.vandapharma.com. Investors should go to the Web site at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Thursday, November 8, 2007, beginning at 12:30 PM ET and will be accessible until Thursday, November 15, 2007, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 60186931.

About Vanda Pharmaceuticals Inc.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder, and has recently submitted an NDA to the FDA for the treatment of schizophrenia. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for sleep disorders. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness in Phase II. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Company Contact:

Steven A. Shallcross

Senior Vice President & CFO

Vanda Pharmaceuticals Inc.

(240) 599-4500

steven.shallcross@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... a Property owned by an affiliate of Seavest, has won a prestigious national ... Southern Chester County ambulatory care center (ACC) was named “Best New Development, MOBs ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. ... DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig ... Life Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... set up in 2006 as a non-profit organization to unite pharmaceutical and healthcare ...
(Date:12/8/2016)... ... 08, 2016 , ... Today’s patients are encouraged to be ... SIGVARIS has created a new line of anti-embolism stockings to help prevent a ... benefits of graduated compression when transitioning from recovery to early rehabilitation. , The ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne Michael ... headquartered in Hamilton County, is embarking on a charity drive with the aim ... new homes for orphaned or neglected senior dogs in the Cincinnati region, and ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , 8 de dezembro de 2016  A Mederi Therapeutics Inc ... Stretta, um tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). ... ... Live Stretta procedure performed and broadcast ... Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)... , Dec. 8, 2016  Pennsylvania Physician ... of Drug and Alcohol Programs Gary Tennis ... insomnia medications, known as benzodiazepines, developed with the ... "Benzodiazepines are medications that are frequently prescribed for ... they are used with opioid pain medications, benzodiazepines ...
(Date:12/8/2016)... 2016 True Health Diagnostics today announced ... services and management expertise to hospital systems throughout ... more doctors and patients to benefit from state-of-the-art ... Logo - http://photos.prnewswire.com/prnh/20161208/447162LOGO ... pressure to contain costs, have struggled to keep ...
Breaking Medicine Technology: